R-Pharm   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Moscow Russian Federation (2001)

Organization Overview

First Clinical Trial
2001
NCT00004927
First Marketed Drug
2007
ixabepilone (ixempra)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Chief Medical Officer, R-Pharm | R-Pharm | R-Pharm International, LLC | R-Pharm Overseas, Inc. | R-Pharm US, Inc. | R-PHARM US LLC